drugset / Trial / NCT01714089

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT01714089

Phase 2 Withdrawn Revalesio Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Interferon beta-1a Protein / enzyme biologic 30 ug Intramuscular
Subject RNS60 Other / unclassified 125 ml Intravenous
Subject RNS60 Other / unclassified 250 ml Intravenous